ESTRO 2024 - Abstract Book

S2268

Clinical - Upper GI

ESTRO 2024

Keywords: oligometastatic disease, metastasectomy, SBRT

References:

1 Kroese TE, van Laarhoven HWM, Nilsson M, et al: Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer 166:254-269, 2022

2 Kroese TE, van Hillegersberg R, Schoppmann S, et al: Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Eur J Cancer 164:18-29, 2022

3 Kroese TE, van Laarhoven HWM, Schoppman SF, et al: Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. Eur J Cancer 185:28-39, 2023

2695

Digital Poster

Radiotherapy for locally advanced pancreatic cancer: SBRT-like approach for all. Results.

Javier Peinado Serrano 1 , Santiago Velazquez Miranda 2 , Pedro Romero Pareja 1 , Sara Estrella Marquez 1 , Isabela Gaztelu Blanco 1 , Ines Ollinger Casin 1 , Jose Luis Lopez Guerra 1 1 University Hospital Virgen del Rocio, Radiation Oncology, Sevilla, Spain. 2 University Hospital Virgen del Rocío, Radiophysics, Sevilla, Spain

Purpose/Objective:

Locally advanced pancreatic cancer (LAPC) currently lacks curable treatment options, and there is ongoing debate about the role of radiotherapy (RT) in this context. The tumor's location and size can limit the total deliverable dose, impacting both local control and the potential for adverse effects. By employing an SBRT-like immobilization and dosimetry approach, which includes simultaneous integrated boost and simultaneous integrated protection (SIB SIP) techniques, it is possible to escalate the dose while safeguarding nearby critical structures. This strategy can be applied in all clinical scenarios.

1- Describe the simulation phase, volume delimitation and dosimetric planning of the plans with SIB-SIP.

2- Analyze the results of local progression-free survival and overall survival (OS) in our cohort of 39 patients treated with normo (N-RT) (28 fractions), moderate- hypo (MH-RT) (10-13 fractions) and extreme-hypo (EH-RT) (5 fractions) fractionated radiotherapy.

Material/Methods: